STOCKS TELEGRAPH

Author: ST Staff

  • Why is Scienjoy Holding Corporation (SJ) stock soaring today?

    Scienjoy Holding Corporation (SJ), a live streaming mobile platform in China, announced the strategic alliance with Snipp Interactive Inc. after which the SJ stock price soared by 40.92% to reach $13.50 a share at the time of this writing. SJ stock was gaining at the previous trading session and its closing per share price of $9.58 was up by 18.42%. Let’s deep dive to explore more of it.

    Strategic Alliance between Scienjoy and Snipp Interactive.

    Scienjoy stock entered the strategic alliance with Snipp Interactive mainly to introduce its New Royalty and Rewards system and secondly it intends to explore Bitcoin and NFT rewards along with Snipps Interactive for its 200 million users and 3 lac broadcasters. Let’s discuss these two areas in detail.

    In connection with the alliance agreement, SJ’s in-app currency solution will be combined with Snipp’s loyalty and rewards engine for the purpose of developing a new reward system. This new system will help SJ stock in identifying its user experience, devise new ways for additional revenue and potential of cryptocurrencies on its platform. Integration with the Snipps platform will make Scienjoy’s broadcasters and users able to earn points through engagement and redeem these points to win various digital rewards. This new reward system will also serve as the monetization channel where brands interested in Scienjoy’s audience would be able to sponsor events as well as broadcasters in addition to live broadcasts.

    Secondly both Scienjoy and Snipp Interactive will work together in SJ’s platform to enable broadcasters to develop their own non-fungible tokens. The users would be able to bid and purchase NFT’s via the points they accumulated through a new reward system from their favorite broadcasters. Broadcasters will have new opportunities for monetization to increase their reputation and strengthen their relationship with their fans.

    SJ’s management perception:

    According to Scienjoy management, a huge audience of SJ stock would help Snipp Interactive to increase its outreach capabilities and its cutting-edge technology and loyalty solutions would further strengthen the value proposition of Scienjoy for both its users and broadcasters that would ultimately benefit SJ in future growth.

    Conclusion:

    So far so good for SJ stock as far as market sentiment is concerned.SJ stock was gaining previously and today’s news of the SJ stock alliance agreement with Snipps Interactive added more hype in the rising stock price. In a nutshell, SJ stock can be a good bet for investors in the long run.

  • Zomedica Corp. (ZOM) stock plunged in the pre-market trading session: here’s why

    Zomedica Corp. (ZOM) stock plunged in the pre-market trading session: here’s why

    Zomedica Corp (ZOM) stock recently traded at $1.33 which is an 8.90% downward movement. The ZOM stock previously closed at $1.46. ZOM stock also plunged in the pre-market trading session by 11.28% at the time of writing.

    The recent pattern of negative movement in the ZOM stock isn’t due to any recent PR news as of April. But this stock has been known to be volatile and gives traders quick short gains or losses if they are not lucky.

    About Zomedica Corp

    Zomedica Corp (NYSE: ZOM) is a veterinary health company that creates commercial products for pets specifically cats and dogs. They focus especially on delivering and innovating products which tend to be the unmet needs of the clinical veterinarians.

    Dwelling deeper into the ZOM stock performance

    Zomedica Corp (ZOM) stock due to its volatility pattern in 2021 would suggest that it should not be kept for the long position. In the month of December 2020, the stock was worth 20-25 cents per share however it entered the year 2021 with a bounce in price up to $1.30 and didn’t stop there. It shot well over the $2 mark and up to $2.91 in February. However, the stock has jumped down from the peak-price climb and now is around $1.30-$1.35 per share.

    If you have experience with trading in for short positions and swift market timing then this stock can definitely give you a reward. For that it is also important that you understand what is the recent operational activities happening in the ZOM stock’s fundamentals;

    Zomedica has released a veterinary diagnosis-kit that has been tailor made and sold known as TRUFORMA. This was delivered on 16th March, ahead of the announced 30th March date. It is an on-site canine eACTH assay that is created for the purpose of eliminating the risk of sample transport error. Furthermore, it aids in the diagnosis of adrenal disease. To learn more, read our article covering this news by clicking here.

    What makes ZOM stock so special?

    With the latest milestone in its flagship product, we need to look into the stats of the pet diagnostic market. The most significant data about the market is that 93% of the dog owners visit veterinary annually and with the average lifespan of dog in mind, that means they will visit for 15 years give or take. Furthermore, 67% of the households keep a single pet at least and $99 billion is the amount that consumers spent on their pets in the US, 2020.

    These stats are very welcoming for Truforma and with other assays in the phase to be released soon, 2021 seems highly for ZOM stock to rise. Zomedica has also submitted an in the company’s SEC 10-K form, a bull thesis which indicates the market potential for companion animal diagnostic market forecasted to reach $2.8 billion  (a 5-year CAGR of 9.8%) by 2024. Similarly, the global veterinary immunodiagnostic market has been forecasted to reach $2.1 billion by 2022 (CAGR 9.6%) This potential is well within reach as the company keeps reaching its milestones one by one.

  • Broadwind Inc. (BWEN) stock rises during pre-market trading session. Why is it so?

    Broadwind Inc. (BWEN) stock rises during pre-market trading session. Why is it so?

    Broadwind Inc. (BWEN) stock declined by 8.56% at the last trading close while the BWEN stock gains in the pre-market session by 3.89%. There is no recent news available related to this change in BWEN stock. Broadwind is a high-precision manufacturer of clean-tech and other specialized structures, machinery, and parts. BWEN’s talented team is focused on helping consumers optimize the performance of their investments—quicker, faster, and smarter with facilities around the United States.

    Recent Developments

    On March 23, 2021, it was being announced that Broadwind has been the subject of an inquiry by Levi & Korsinsky into alleged violations of fiduciary duty. Levi & Korsinsky is a widely renowned firm with considerable experience pursuing securities cases alleging financial fraud, defending plaintiffs in securities lawsuits around the country, and recovering hundreds of millions of dollars for aggrieved shareholders.

    Financial Results 2020

    A while ago on February 25, 2021, BWEN stock announced its fourth quarter and full-year 2020 financial results. Given below is the summary:

    • The total revenue generated for the full year 2020 was $198.5 million and for the fourth quarter, it was $40.3 million. This is an increase of 11% and 18% compared to Full-year and fourth quarter 2019, respectively.
    • BWEN’s gross profit for the year 2020 was $18.0 million, an increase of 17% compared to the previous year. Whereas the gross profit for fourth quarter 2020 was $2.7 million which again is an increase of 33% compared to fourth quarter 2019.
    • The net loss for the fourth quarter of 2020 was $2.0 million or $0.12 per basic share.
    • Lastly, the total non-GAAP adjusted EBTIDA for the full year 2020 was $8.0 million and for the fourth quarter it $0.3 million.

    Conclusion

    Since there is no recent news available, following the current change in BWEN stock, it can be only assumed that due to these recent developments especially the inquiry going on against BWEN, is might be the reason that BWEN stock is showing uncertainty. Until the final verdict comes out related to the inquiry, it is quite obvious that investors would be unsure about making any long-term investment in BWEN shares.

  • Why did Naked Brand Group Limited (NAKD) stock fall in Pre-Market today?

    Why did Naked Brand Group Limited (NAKD) stock fall in Pre-Market today?

    Shares of Naked Brand Group Limited (NAKD) stock were down today in the Pre-Market trading session.NAKD stock price was down by 2.14% to drop at $0.68 a share as of this writing. It seems that NAKD is not performing well in recent times as it was down by 2.10% at the previous closing. Let’s try to understand the current scenarios of NAKD stock.

    What’s happening?

    Naked Brand Group Limited (NAKD) is the leading company in intimate apparel and sells its products in Australia, New Zealand, United States, and Europe through offline and online mediums. NAKD stock performed well in early 2021 but it seems that NAKD is again falling back to earth for the past couple of months. Currently, we find no specific news by the Naked Brand to justify this bearish sentiment. Furthermore, there are no signs of analysts downgrades or shrank targeted per share price of NAKD. A situation like this spreads confusion among investors as one group of investors thinks of it as the opportunity to buy while the other group shows reluctance to take any decision. So what you need to know at this time? Let’s look at the business development of NAKD stock.

    Business Development:

    On March 29, 2021, Naked stock announced that it had completed multiple strategic capital financing that resulted in the net proceeds of $270 million and weaned itself from debt obligations. Moreover, NAKD is in the final stages of getting shareholder approval for divestiture of its brick-and-mortar operations. Divestiture of Bendon Brick-and-Mortar operations is expected to be complete in the second quarter of 2021.

    Following the current scenarios, NAKD Management is focused on the advancement and expansion of  E-commerce business in order to meet the requirements of the digital world and making Naked Brand, a lead, in the intimate apparel market. Fortunately, Naked stock has a considerable amount in its balance sheet to support the development of Naked’s digital transformation.

    Conclusion:

    Things are gloomy for NAKD stock as far as market sentiment is concerned. The good part is that NAKD stock is free from debt and has sufficient capital for the growth of its eCommerce business. But there is a big question mark whether Naked’s efforts for its eCommerce business would prove to be fruitful or not as many big brands are still struggling due to great competition. Hence investors should consider all the pros and cons in addition to fundamental and technical analysis of Naked stock before taking any decision.

  • Playboy Enterprises Inc. (PLBY) stock gains in the pre-market trading session. Let’s find out why?

    Playboy Enterprises Inc. (PLBY) stock gains in the pre-market trading session. Let’s find out why?

    Playboy Enterprises Inc. (PLBY) stock surged by 19.46% at the last trading close while the PLBY stock continued to rise by 5.59% in the pre-market trading session. The rise in PLBY stock is not followed by any recent news or update. PLBY Group provides products, facilities, and experiences to customers all over the world to make them look good, feel good, and have fun. Sexual Health, Style & Fashion, Gaming & Lifestyle, and Beauty & Grooming are the four main categories that PLBY Group represents.

    Financial Results 2020

    On March 24, Playboy Enterprises announced its financial results for fourth quarter and full year 2020. Given below is the summary:

    • The revenue generated for the full year 2020 was $147.7 and $46.3 million for the fourth quarter which was a rise of 89% and 118% respectively, compared to previous year.
    • The operating income for the year 2020 was $13.6 million compared to $19.6 million for the full year 2019. Whereas the operating expense for the fourth quarter 2020 was $4.9 million compared to $8.7 million from the previous year’s fourth quarter.
    • The net loss calculated for the year 2020 was $5.3 million compared to $18.3 million for the year 2019, while the net loss for the fourth quarter 2020 was $0.5 million relative to $5.5 million for the previous year’s fourth quarter.
    • In 2020, adjusted EBITDA was $28.3 million, including $6.5 million in the fourth quarter. Out-of-period costs totaled $2.2 million in the fourth quarter EBITDA.

    Furthermore,

    The CEO of PLBY Group Ben Kohn said that they are very pleased with their fourth-quarter and full-year 2020 performance. Despite the pandemic’s turbulence, their diversified international operations generated $46 million in fourth-quarter revenue, up 118 percent year over year, and $148 million in full-year revenue, up 89 percent year over year. Their revenue growth increased across the board, due to the expansion of direct-to-consumer digital commerce sales and a 20% annual increase in our highly profitable licensing business.

    He further added that in 2021, PLBY is off to a strong start, and they’re increasing their sales forecast to more than $200 million this year. As a high-growth consumer lifestyle business, PLBY’s primary emphasis is on accelerating sales growth in order to provide significant long-term value to our shareholders.

  • Weidai Ltd (WEI) stock soared in the pre market trading session: here’s why

    Weidai Ltd (WEI) stock recently traded at $1.41 which is a 2.76% downward movement. The WEI stock previously closed at $1.41. WEI stock also soared in the pre-market trading session by 39.72% at the time of writing.

    The recent pattern of positive movement in the after-hours trading session does not come along with any recent relevant news or press release.

    Weidai Ltd provides credit to its clients

    Weidai Ltd. is a software-application based company that specifically provides risk management system and financing solution services. In China, it is considered the pioneer for service provision of its kind. Weidai Ltd. provides auto-backed financing solutions to its clients. WEI does it through giving small and micro enterprises in China an option to give their old and used automobiles as “non-standard” collateral for WEI stock to use as an investable assets and then provide credit. The company also provides connections to borrowers with institutional funding partners through its platform.

    Announcement of Full Year 2020’s financial result

    Weidai Ltd. announced the release of its financial results for its full-year 2020 report, on 19 March 2021. The financial results were not reviewed by the WEI’s independent registered accounting firm.

    The auto-backed financing solution provider has stated that its loan balance for the year 2020 till the end of 31 December 2020 was RMB4.5 billion which is equivalent to $0.7 billion which is a drastic drop from RMB13.7 billion in 2019.

    NOTE: All conversions of RMB to US is based on the noon buying rate on 31 December 2020 as set forth by U.S Federal Reserve Board – RMB6.5250 to US$1.0

    Furthermore, the provision for loans and advances as of 2020 was RMB803.7(US$235.4) compared to RMB1162 in 2019.

    WEI stock’s Full Year 2020’s net revenue totals at RMB1536.1 million(US$235.4 million) compared to RMB3375 million in 2019. Breaking these net revenues down, we gather that 2020’s;

    • loan service fee for 2020 is RMB 1,411.1 million(US$216.3 million)as compared to RMB2,955 million in 2019
    • Other revenues in WEI for 2020 was RMB97.8 million (US$15 million)as compared to RMB273.4 million in 2019
    • Net financing income in 2020 was RMB30.8 million (US$4.7 million)compared to RMB144.8 million in 2019

    Operating costs and expenses of the WEI stock are at a total RMB 1,141 million(US$174.9 million) compared to RMB1909.5 million. Among these costs are;

    • Provision for financial guarantee liabilities in 2020 was RMB 103.0 million(US$123.2 million) – RMB19.2 million in 2019
    • Expenses for originating and servicing were at RMB766.3 million(US$15.8 million) – RMB1388.6 million in 2019
    • Sales and Marketing expenses for 2020 were RMB15.1 million(US$117.4 million) – RMB138.1 million in 2019
    • Research and Development expenses for 2020 were RMB27.1 million(US$4.2 million) – RMB81.7 million in 2019

    FY 2020 also shows that share based compensation expenses in 2020 were RMB 6.1 million(US$0.9 million).

    WEI stock has reported a net loss in 2020 of RMB714.3 million(US$109.5 million) as compared to the net income in 2019 of RMB263.2 million. Furthermore, the ordinary shareholders of the WEI stock also had a net and comprehensive loss of RMB712.6 million(US$109.2 million). In 2019 the ordinary shareholders had gained RMB253.6 million.

    SEC regulatory involvement in Weidai Ltd

    Along with the financial report Weidai Ltd. has also reported that it is cooperating fully with SEC and government authority for the smooth peer-to-peer exit. Since the regulatory guidance issued by the PRC government in 2019, the guidance states the full exiting of the peer-to-peer industry. This is done in order for the transformation of online lending information intermediary institutions into pilot micro credit companies.

  • DiaMedica Therapeutics Ltd. (DMAC) stock goes down in the after-hours trading session: here’s why

    DiaMedica Therapeutics Ltd. (DMAC) stock recently traded at $9.81 which is a 0.82% upward movement. The DMAC stock previously closed at $9.73. DMAC stock, however, dropped in the after-hours trading session by 9.79% at the time of writing.

    The recent downward pattern of stock movement in the after-hours trading session has no direct association with the recent news. However as for the news, DMAC stock announced that it is presenting research at the NKF 2021 meeting.

    DiaMedica Therapeutics’ focus on neurological and renal diseases

    DiaMedica Therapeutics (DMAC) Inc. is a clinical stage biopharmaceutical company that specializes in developing various treatments that can innovatively be produced to tackle the unmet need of neurological and chronic kidney disease patients. The novel treatment developments will initially focus on acute ischemic stroke (AIS) and chronic kidney disease (CKD).

    DMAC participates in NKF’s 2021 SCM

    The DMAC stock Company has announced that the presentation will be held at the National Kidney Foundation 2021. Specifically, it will present two abstracts at the spring clinical meetings for 2021.

    National Kidney Foundation is a massive organization that is leading the mission for awareness of the Kidney diseases as well as its preventions and treatments. This platform allows for the awareness to be spread among millions of patients with the kidney-related disease and thousands of doctors, renal healthcare professionals and experts in America.

    Springs Clinical Meetings provides a platform opportunity as an educational conference for health care providers to learn newly-made researches and developments all associated with the different aspects of nephrology. SCM showcases an important objective to specifically learn about chronic kidney diseases. This allows participants to be aware and updated on the new developments on kidney diseases made by the health community. It does this through a combination of courses and workshops. Currently, there are 30 million Americans affected with chronic kidney diseases; one out three people at a risk from the 9th leading cause of death in the US.

    Since the covid-19 pandemic has discouraged people from meeting in public and physically, the meeting will be held in a virtual conference from 6th April to 10th April. DMAC stock will participate in the meeting with the two abstracts it has prepared. The subject of one abstract is about the level of kallikrein protein levels comparatively present in the body of a patient with chronic kidney disease and a healthy person’s normal kidney function. The second abstract is about DMAC’s multicenter, open-lab study ofDM199 in patients of chronic kidney diseases of stage 2 or 3. This study will be a Redux based study.

    DMAC’s 2020 financial performance momentum can carry it through mid-2022

    On 11 March 2021, DiaMedicareleased the Full Year financial report 2020 to present the performance of its operations and thus DMAC stock’s performance. Here it also discussed the business updates which include a very active participation in presentations, conferences and webinars of international scale to discuss its ReMEDy phase 2 trial data and initiations of phase 2/3 trials for AIS in 2021.

    The 2020 financial highlights indicated that;

    • In 2020, DMAC stock completed two underwritten public offerings of its common shares for gross proceed of $28.8M and $31.5M.
    • DMAC at the end of the year incurred $27.5M in cash and cash equivalents.

    DiaMedica Therapeutics stated in its balance sheet segment that these net proceeds and capital are sufficient to provide funds throughout mid-2022 along with the initiation of its AIS phase2/3 trial and completion of REDUX trial.

  • Kelso Technologies Inc. (KIQ) stock surges in the after-hour trading. Here’s to know why?

    Kelso Technologies Inc. (KIQ) stock plunged by 8.32% at the last trading close whereas the KIQ stock price rises by 4.03% in the after-hour trading session. As of now, there is no update available regarding this swing in KIQ stock while KIQ has recently released its full year 2020 financial results. Kelso is a multi-faceted design and development firm that specializes in the manufacture, and distribution of patented transportation service equipment.

    Financial Results 2020

    • Kelso Technologies has generated a revenue of $11,149,130 for the year 2020 compared to $20,550,682 in the previous year.
    • The Gross profit for the year 2020 was $4,792,678 whereas the gross profit calculated in the year 2019 was $9,582,879.
    • Operating Expenses were $5,768,476 for the full year ended on December 31, 2020 relatively the value was $6,087,357 for the last year.
    • The net loss calculated by KIQ stock for the year 2020 was $1,307,890 whereas the net income of Kelso Technologies for the previous year was $3,334,043.
    • And lastly the EBTIDA calculated for the year 2020 was $366,157 compared to $4,233,339 for the year 2019.

    Kelso’s financial success in 2020 was affected by a 46 percent decrease in sales operation from the previous year, but operating expenses cut by 5%, enabling the company to remain cash flow positive (net of non-cash items). The severity of the potential threat to KIQ stock business survival was highlighted by this economic downturn.

    Conclusion

    COVID-19 reshaped the market dynamics of the rail tank car industry, causing Kelso to suffer a significant economic setback in 2020. Given the pandemic’s unparalleled challenges, KIQ’s primary emphasis is on limiting negative effects on its business model and protecting its key productive assets. Now in the year 2021, KIQ stock is focusing on post-pandemic normalization, planned product creation, and getting ready for a strong restart of business growth.

  • AgEagle Aerial Systems Inc. (UAVS) stock declines in the after-market trading. Why is it so?

    AgEagle Aerial Systems Inc. (UAVS) stock declines in the after-market trading. Why is it so?

    AgEagle Aerial Systems Inc. (UAVS) stock surged by 14.32% at the last trading close whereas the UAVS stock price plunges by 3.83% in the after-market trading session, after the official announcement being made by Levi & Korsinsky that a securities class action lawsuit has been filed against UAVS. AgEagle’s focuses on high performance, next-level thought, and technical creativity, and it was among the few initiators in the delivery of advanced commercial drone technology, facilities, and solutions. Their goal is to create a completely new level for high-quality drone manufacturing in the United States.

    What is happening?

    On April 5, 2021, Levi & Korsinsky clarified that all individuals or organizations who purchased or acquired securities of UAVS between September 3, 2019, and February 18, 2021, should be aware that a securities class action lawsuit has been filed in the Central District of California by the United States District Court.

    Defendants made false statements and failed to report the following during the class period, according to the complaint:

    • UAVS was not in any collaboration with Amazon in fact it never had any link with Amazon in the past as well.
    • About their partnership with Amazon, the defendants were conveniently supporting the rumor that they have a relationship with Amazon rather than clarifying the public about it.
    • As a consequence, at all relevant times, Defendants’ claims about AgEagle’s company, activities, and prospects were significantly under – represented, and lacked a fair basis.

    The public has also been informed that anyone who hasfaced a loss in AgEagle can request the Court to appoint them as lead plaintiff till April 27, 2021. It is not necessary for you to be a lead plaintiff in order to share in any compensation.

    Levi & Korsinsky;

    With offices in New York, California, Connecticut, and Washington, D.C., Levi & Korsinsky is a nationally known company. The firm’s lawyers have considerable experience defending investors in securities cases and have helped shareholders recover hundreds of millions of dollars.

  • Bio-Path Holdings Inc (BPTH) Stock Has Surged 13.99% At $8.15 In current market Trading. Here’s What Happened

    Bio-Path Holdings, Inc., (BPTH) stock price increased by a staggering 13.99% after it announced the successful completion the safety run-in of Stage 2 of Phase 2 of its clinical study today, for the treatment of acute myeloid leukemia (AML). The safety run-in of Stage 2 of Phase 2 clinical trial consisted of six people effected with AML, who were evaluated and treated with a combination drugs providing a clean side effect profile and no toxicity.

    The efficacy signals in the data set also gave encouraging news about the treatment with five of six diagnosed AML patients showing clinical activity.

    The Phase 2 clinical trial currently consists of  21 patients present among all three groups. Accommodation of 19 patients in each group would provide an adequate analysis for comparative efficacy review compared with decitabine and venetoclax combination therapy. A positive efficacy result may mean an accelerated approval rate by FDA, with phase 2 of the trials being performed at up to 10 clinical sites.

    Corporate Bio-Path Holdings, Inc Highlights

    BPTH gained $13.0 Million from a Public Offering, consisting of 1,710,600 shares of common stock which was shared to the public for $7.60, Bio-path gaining a staggering $13M as financial surplus, before subtracting the fees and expense payable by the biotechnology company.

    Bio-Path also reported that their product was officially patented and given the title, “P-ethoxy nucleic acids for liposomal formulation.” The new patent protects the platform technology of the nanoparticle drug and gives all rights to BPTH for production.

    Conclusion

    If BPTH can deliver a drug enhancing the treatment of acute myeloid leukemia (AML), BPTH stock could have a serious capital gain. If the company has halted trials, BPTH shares could have an incredible plummet. Hence the clinical trials play a significant role in deciding the future valuation of the company.